Compare RPC & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RPC | VALN |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | France |
| Employees | 267 | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.7M | 875.7M |
| IPO Year | N/A | 2021 |
| Metric | RPC | VALN |
|---|---|---|
| Price | $7.63 | $10.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $11.00 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 744.1K | 17.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.96 | $2.58 |
| Revenue Next Year | $13.18 | $4.43 |
| P/E Ratio | $53.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.51 | $5.43 |
| 52 Week High | $9.32 | $12.25 |
| Indicator | RPC | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 53.01 |
| Support Level | $7.63 | $8.37 |
| Resistance Level | N/A | $12.22 |
| Average True Range (ATR) | 0.36 | 0.40 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 8.79 | 35.11 |
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.